Lexeo Therapeutics, Inc. (LXEO) Price & Analysis

Compare

185 Followers

LXEO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.45 - $11.72

Previous CloseN/A

Volume22.32K

Average Volume (3M)1.04M

Market Cap

$444.97M

Enterprise Value$51.19M

Total Cash (Recent Filing)$132.89M

Total Debt (Recent Filing)$8.91M

Price to Earnings (P/E)―

Beta1.95

Next Earnings

Dec 15, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding54,001,213

10 Day Avg. Volume1,555,178

30 Day Avg. Volume1,039,976

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue26.33

Enterprise Value/Gross Profit-93.41

Enterprise Value/Ebitda-0.46

Forecast

1Y Price Target

$18.40

Price Target Upside124.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Price TargetThe price target is raised to $15, reflecting formal FDA alignment and risk-mitigated timelines.

Regulatory ApprovalThe FDA has indicated openness to a BLA submission for accelerated approval that includes clinical data from the ongoing phase 1/2 studies of LX2006 pooled with new clinical data from the planned pivotal study.

Safety ProfileLX2006 has been generally well tolerated with no grade 3+ serious adverse events to date, and no clinically significant complement activation or signs of frataxin over-expression observed in cardiac tissue.

Bears Say

Financial OutlookLXEO ended the period with $152.5mm in cash and equivalents, expected to fund future developments.

Price Target ReductionThe price target for LXEO was reduced from $10 to $9.

Regulatory UncertaintyLXEO is seen as well-positioned compared to gene therapy peers despite regulatory uncertainty.

Lexeo Therapeutics, Inc. News

Lexeo Therapeutics price target raised to $17 from $15 at Chardan

Chardan raised the firm’s price target on Lexeo Therapeutics (LXEO) to $17 from $15 and keeps a Buy...

7d ago

LXEO

IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz

The major averages were broadly lower, curtailing some recent gains as the U.S. government shutdown enters its seventh...

7d ago

Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $9 and keeps a...

7d ago

LXEO

Lexeo Therapeutics price target raised to $20 from $9 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $9 and...

7d ago

LXEO

Morning Movers: IntercontinentalExchange up after $2B investment in Polymarket

Stock futures are muted as investors sit on their hands ahead of fresh cues from Fed speakers and...

7d ago

BTM

IBM

Lexeo Therapeutics up 31% at $8.50 after update on LX2006 accelerated approval

07:52 EDT Lexeo Therapeutics (LXEO) up 31% at $8.50 after update on LX2006 accelerated approval Published first on...

7d ago

LXEO

Lexeo Therapeutics reports on LX2006 approval pathway

Lexeo Therapeutics (LXEO) announced updates to key components of an Accelerated Approval pathway for LX2006 in Friedreich ataxia,...

7d ago

LXEO

Citizens JMP healthcare analysts hold an analyst/industry conference call

Halthcare Analysts discuss the patiet community perspective on Friedreich’s Ataxia (relevant companies LRMR BIB PTCT LXEO DSGN) on...

13d ago

BIIB

DSGN

Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on LXEO stock, giving a Buy rating yesterday....

6d ago

LXEO

Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on Lexeo Therapeutics, Inc. and increased the price...

7d ago

LXEO

Lexeo Therapeutics Advances FDA Discussions for LX2006

Lexeo Therapeutics, Inc. ( ($LXEO) ) has issued an update. On October 7, 2025, Lexeo Therapeutics announced progress...

7d ago

LXEO

Lexeo Therapeutics price target lowered to $15 from $20 at Chardan

Chardan lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $20 and keeps a Buy...

2M ago

LXEO

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc.,...

2M ago

LXEO

Lexeo Therapeutics price target lowered to $9 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $9 from $15 and keeps a...

2M ago

LXEO

LXEO FAQ

What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?

Lexeo Therapeutics, Inc. lowest stock price was $1.45 and its highest was $11.72 in the past 12 months.

What is Lexeo Therapeutics, Inc.’s market cap?

Lexeo Therapeutics, Inc.’s market cap is $444.97M.

When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?

Lexeo Therapeutics, Inc.’s upcoming earnings report date is Dec 15, 2025 which is in 62 days.

How were Lexeo Therapeutics, Inc.’s earnings last quarter?

Lexeo Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.679 by $0.079.

Is Lexeo Therapeutics, Inc. overvalued?

According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lexeo Therapeutics, Inc. pay dividends?

Lexeo Therapeutics, Inc. does not currently pay dividends.

What is Lexeo Therapeutics, Inc.’s EPS estimate?

Lexeo Therapeutics, Inc.’s EPS estimate is -0.52.

How many shares outstanding does Lexeo Therapeutics, Inc. have?

Lexeo Therapeutics, Inc. has 54,001,213 shares outstanding.

What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?

Lexeo Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.679. Following the earnings report the stock price went up 1.483%.

Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LXEO

Lexeo Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-75.32%

Trailing 12-Months

Asset Growth

-8.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. (LXEO) is a biotechnology company focused on developing gene therapy treatments for genetic cardiovascular diseases, central nervous system disorders, and rare monogenic disorders. The company leverages advanced scientific research to create innovative therapies aimed at addressing unmet medical needs and improving patient outcomes.

Lexeo Therapeutics, Inc. (LXEO) Earnings & Revenues

Historic Earnings Reports

LXEO Stock 12 Month Forecast

Average Price Target

$18.40

▲(124.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,7.667692307692308,8.695384615384615,9.723076923076922,10.75076923076923,11.778461538461539,12.806153846153846,13.833846153846153,14.861538461538462,15.889230769230767,16.916923076923077,17.944615384615386,18.97230769230769,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,7.544615384615384,8.449230769230768,9.353846153846153,10.258461538461537,11.163076923076922,12.067692307692306,12.972307692307691,13.876923076923076,14.78153846153846,15.686153846153843,16.59076923076923,17.495384615384612,{"y":18.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,7.283076923076923,7.926153846153846,8.569230769230769,9.212307692307691,9.855384615384615,10.498461538461537,11.14153846153846,11.784615384615384,12.427692307692308,13.07076923076923,13.713846153846152,14.356923076923074,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >